Authors
Loading...
Regulatory change allows reliance on animal-free alternatives before human trials, indicating a shift in drug approval processes.
Meredith Wadman (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: